Download - Present, Collect & Lead using iPads
Find out here
WELCOME TO
Use your iPad to present
your brand news &
co l lec t cus tomer data !
D E M O P R E S E N TAT I O N
Why MReply is your best brand partner in digital communication?
Animation
Loop
Animation
Triggering
Navigation in
Presentation
Types of
Answers
What makes MReply unique for consumer?
Additional benefits for your business
Your story in pictures with captivating animations and infinite play before and without user input or any interaction
1A) Animation Loop – Products Rotation
slider 900x100
Display and rotate any creative visuals you like: square ~ slider ~ full-branding ~ pop-up ~ interstitial and more…
1B) Animation Loop - Display Ad Formats
square 300x300
2) Animation TriggeringLet your consumers choose from different products andexpose them to captivating visual content
Use inner connections between slides to get to specific slide
3) Navigation in Slides
Scale option4A) Options – Single Select
Select option by clicking on images
DRESSES
TOPS JEANS TROUSERS
Scale option4B) Feedback
Select satisfaction level
DRESSESHow satisfied are you with the product?
We will send special prices voucher
SEE YOU ON SEPTEMBER 1st
By clicking Submit, I accept privacy statement
Name:
Surname:
Phone:
Email:
4C) FormsFill out forms with intelligent keyboard or by voice
4C) Type of answers
How much do
you like Acidko
yoghurt? (Rank
1-10 )
Describe the taste
with your words
❶
SELECT
❷
INPUT A
❸
INPUT B
4C) FlowFlow of answers can be easilydesigned by your needs
How much do
you like Acidko
yoghurt? (Rank
1-10 )
Describe the taste
with your words
❶
SELECT
❸
INPUT A
❷
INPUT B
Try it out, tapping on both of the
bottles
Team management
Add your team members and select user rights (Agent,
Supervisor, …)
Realtime overview of your team performance
you
supervisor
agent
Performance management
Manage your KPIs, compare your team members performance easily
Agent 2
Agent 1
Database + Export
Direct access to all Q&As for every data input entry Ready for your CRM import Simple versioning system
Customer connectivity
Further analysis and connectivity on demand
SMS instant feedback
E-mail messaging
SMS
LET’S TALK
ABOUT YOUR
BUSINESS
NEEDS
NOW
LET’S TALK ABOUT YOUR BUSINESS NEEDS
SEND
Please, send me examples of latest presentations
THANK
YOU!We will
help you to promote
your brand too!
ACIP RecommendationsSupport
ACIP recommends that a MenB vaccine series may be administered to adolescents and
young adults aged 16 through 23 years to provide short-term protection against most
strains of MenB disease. The preferred age for MenB vaccination is 16 through 18
years. The decision to vaccinate should be made at the individual level by healthcare
providers.
ACIP recommends certain persons aged ≥10 years who are at increased risk for
meningococcal disease should receive MenB vaccine. These persons include:
• Persons with persistent complement component deficiencies
• Persons with anatomic or functional asplenia, including sickle cell disease
• Microbiologists routinely exposed to isolates of Neisseria meningitidis
• Persons identified as at increased risk because of a MenB disease outbreak
Individuals at increased risk for MenB should be vaccinated, according to ACIP
How Trumenba worksSupport
TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H
binding protein (fHBP)—which is found on more than 97% of all MenB strains.
This method generates antibodies capable of destroying a range of MenB strains.
TRUMENBA targets a protein found in >97% of MenB strains
The fHBP Discovery
Pfizer used a combined biochemical and immunological screening approach to identify
surface-expressed proteins on MenB strains that were capable of producing antibodies
that could kill diverse meningococcal strains. During this process, fHBP elicited robust
bactericidal responses
Cross-CoverageSupport
TRUMENBA demonstrated cross-
coverage by targeting MenB
strains expressing both
subfamilies, A and B, of fHBP
TRUMENBA is the only MenB
vaccine that was tested against 4
prevalent strains in the US and
Europe
*In a randomized, placebo-controlled, single-blinded, multicenter trial conducted in Europe, 1713 adolescents 11 through 18 years of age were assigned randomly into 5 groups to receive 2 or 3 doses of TRUMENBA: Group 1 (0, 1, and 6 months); Group 2 (0, 2, and 6 months); Group 3 (0 and 6 months); Group 4 (0 and 2 months); Group 5 (0 and 4 months).1,2
†To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline hSBA titer ≥1:4, an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.